Dr. Cong Xu, MD, PhD, MBA, has over 10-year experiences in pre/clinical research and medical affairs in oncology. He is Managing Director of Lilly Asia Ventures. Prior to that, he was Medical Director at Eli Lilly. Dr. Cong Xu led new drug development from strategy to operation across various tumor types including abemaciclib, a CDK4/6 inhibitor. He led investments such as EdiGene, Allist, Dizal, Mirati, Cullinan, ImmuneOnco etc. Dr. Xu obtained his PhD in Clemson University and MBA degree from The University of British Columbia.